X T L Biopharmaceuticals Ltd
Change company Symbol lookup
Select an option...
XTLB X T L Biopharmaceuticals Ltd
RBLX Roblox Corp
JMIA Jumia Technologies AG
MYDX MyDx Inc
WHF WhiteHorse Finance Inc
INDB Independent Bank Corp (Massachusetts)
SNOW Snowflake Inc.
FAUDX Strategic Advisers® Short Duration Fund
FFBC First Financial Bancorp
SMEBF Sime Darby Bhd
Go

Health Care : Biotechnology | Small Cap Value
Based in Israel
Company profile

XTL Biopharmaceuticals Ltd., incorporated on March 9, 1993, is a biopharmaceutical company. The Company is engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company’s developed drug candidate is hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). Its hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. Its rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM).

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$4.45
Day's Change
0.30 (7.23%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.69
Day's Low
4.00
Volume
(Heavy Day)
Volume:
3,989,602

10-day average volume:
377,732
3,989,602

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Peloton Interactive, Inc. of Class Action Lawsuit and Upcoming Deadline - PTON

12:40 am ET June 11, 2021 (PR Newswire) Print

Pomerantz LLP announces that a class action lawsuit has been filed against Peloton Interactive, Inc. ("Peloton" or the "Company")(NASDAQ: PTON) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 21-cv-02925, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired the publicly traded securities of Peloton between September 11, 2020 and May 5, 2021, inclusive (the "Class Period"). Plaintiff seeks to recover compensable damages caused by Defendants' violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act").

https://mma.prnewswire.com/media/1486339/Pomerantz_Logo.jpg

If you are a shareholder who purchased Peloton securities during the Class Period, you have until June 28, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

Peloton provides interactive fitness products such as the Peloton Bike and the Peloton Tread+ and Tread, which include touchscreens that stream live and on-demand classes. Peloton also provides connected fitness subscriptions and access to live and on-demand classes.

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) in addition to the tragic death of a child, Peloton's Tread+ had caused a serious safety threat to children and pets as there were multiple incidents of injury to both; (ii) safety was not a priority to Peloton as Defendants were aware of serious injuries and death resulting from the Tread+ yet did not recall or suggest a halt of the use of the Tread+; (iii) as a result of the safety concerns, the U.S. Consumer Product Safety Commission ("CPSC") declared the Tread+ posed a serious risk to public health and safety resulting in its urgent recommendation for consumers with small children to cease using the Tread+; (iv) the CPSC also found a safety threat to Tread+ users if they lost their balance; (v) Tread featured similar safety concerns; (vi) merely reinforcing safety warnings would be insufficient; (vii) the CPSC and Peloton would issue a recall of the Tread+ and Tread; (viii) issues with the Tread+ and Tread were not patchable via software updates; (ix) Defendants were not fully cooperating with the CPSC; (x) as opposed to Defendants' statements, CPSC statements were not misleading or inaccurate; and (xi) as a result of the foregoing, Defendants' statements about Peloton's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On April 17, 2021, a day the market was closed, the CPSC issued a press release entitled "CPSC Warns Consumers: Stop Using the Peloton Tread+" alerting the public to dangers, including death, associated with the Peloton Tread+.

That same day, Peloton issued a press release entitled "PELOTON REFUTES CONSUMER PRODUCT SAFETY COMMISSION CLAIMS: CPSC PUBLISHES MISLEADING, INACCURATE BULLETIN ON TREAD+ PRODUCT SAFETY" which attempted to rebut the CPSC's warnings.

Following these disclosures, Peloton's stock price fell $16.28 per share, or 14%, over the next three trading days to close at $99.93 per share on April 21, 2021, damaging investors.

Then, on May 5, 2021, during market hours, the CPSC issued a statement entitled "Statement of Acting Chairman Robert Adler on the Recall of the Peloton Tread + and Tread" which announced that the CPSC and Peloton had come to an agreement to protect users of the Peloton Tread+ and Tread products, which required Peloton to immediately stop selling and distributing both the Tread+ and Tread products in the United States and refund the full purchase price to consumers who wish to return their treadmills.

That same day, Peloton posted an article entitled "CPSC and Peloton Announce: Recall of Tread+ Treadmills After One Child Death and 70 Incidents; Recall of Tread Treadmills Due to Risk of Injury" to its website, which, among other things, acknowledged that Peloton made a mistake in its initial response to the CPSC's request that Defendants recall the Tread+ and should have engaged more productively with the CPSC from the outset.

Following these disclosures, Peloton's stock price fell $14.08 per share, or 14.56%, to close at $82.62 per share on May 5, 2021, further damaging investors.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

Contact:

Robert S. WilloughbyPomerantz LLPrswilloughby@pomlaw.com 888-476-6529 ext. 7980

https://c212.net/c/img/favicon.png?sn=DC08184&sd=2021-06-11

View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-peloton-interactive-inc-of-class-action-lawsuit-and-upcoming-deadline--pton-301310676.html

SOURCE Pomerantz LLP

https://rt.prnewswire.com/rt.gif?NewsItemId=DC08184&Transmission_Id=202106110040PR_NEWS_USPR_____DC08184&DateId=20210611

comtex tracking

COMTEX_388123130/1005/2021-06-11T00:40:11

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.